These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35019167)

  • 1. Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network.
    Reynolds WS; Suskind AM; Anger JT; Brucker BM; Cameron AP; Chung DE; Daignault-Newton S; Lane GI; Lucioni A; Mourtzinos AP; Padmanabhan P; Reyblat PX; Smith AL; Tenggardjaja CF; Lee UJ;
    Neurourol Urodyn; 2022 Feb; 41(2):662-671. PubMed ID: 35019167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic use, best practice statement adherence, and UTI rate for intradetrusor onabotulinumtoxin-A injection for overactive bladder: A multi-institutional collaboration from the SUFU Research Network (SURN).
    Shapiro K; Anger J; Cameron AP; Chung D; Daignault-Newton S; Ippolito GM; Lee U; Mourtzinos A; Padmanabhan P; Smith AL; Suskind AM; Tenggardjaja C; Van Til M; Brucker BM
    Neurourol Urodyn; 2024 Feb; 43(2):407-414. PubMed ID: 38032120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for adverse events following intravesical botulinum toxin injections in men.
    Ribeiro L; Leung LY; Tan N; Low ZY; Nagarajah M; Ahmed G; Carey M; Sabbagh S; Sharma D; Seth J
    Neurourol Urodyn; 2023 Sep; 42(7):1499-1505. PubMed ID: 37386824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in Defining Retention After Onabotulinum Toxin A for Overactive Bladder: A Systematic Review.
    Castaneda PR; Chen A; Kuhlmann P; Anger JT; Eilber KS
    Urogynecology (Phila); 2024 Sep; 30(9):736-741. PubMed ID: 38465990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Correlation of Diabetes Mellitus and Urinary Retention From Intravesical OnabotulinumtoxinA Injection for Overactive Bladder.
    Takashima Y; Handler S; Laus K; Eckhardt S; Whitaker T; Tenggardjaja C; Yazdany T
    Urogynecology (Phila); 2023 May; 29(5):511-519. PubMed ID: 36730351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
    Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS
    Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Retention After OnabotulinumtoxinA Injection for Overactive Bladder in a Diverse Urban Population With High BMI and Comorbidity Rates.
    Aalami Harandi A; Nauheim J; Abraham NE
    Urogynecology (Phila); 2023 Jan; 29(1):41-47. PubMed ID: 36548104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are we underestimating urinary retention following intravesical onabotulinumtoxinA in women with overactive bladder and a history of prior pelvic surgery?
    Holmes A; Kelsey E; Wombwell A; Molesworth C; McLeod K
    Neurourol Urodyn; 2023 Jan; 42(1):106-112. PubMed ID: 36183370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder.
    Eckhardt SE; Takashima Y; Handler SJ; Tenggardjaja C; Yazdany T
    Int Urogynecol J; 2022 Mar; 33(3):703-709. PubMed ID: 33594517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does a Recent Urinary Tract Infection Increase the Risk of Postprocedure Urinary Tract Infection After Onabotulinum Toxin A?
    Bickhaus JA; Bradley MS; Amundsen CL; Visco AG; Truong T; Li YJ; Siddiqui NY
    Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):121-125. PubMed ID: 31295185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease.
    Vurture G; Peyronnet B; Feigin A; Biagioni MC; Gilbert R; Rosenblum N; Frucht S; Di Rocco A; Nitti VW; Brucker BM
    Neurourol Urodyn; 2018 Nov; 37(8):2669-2677. PubMed ID: 29767449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated with Incomplete Bladder Emptying in Older Women with Overactive Bladder Symptoms.
    Park J; Palmer MH
    J Am Geriatr Soc; 2015 Jul; 63(7):1426-31. PubMed ID: 26133000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
    Nik-Ahd F; Lenore Ackerman A; Anger J
    Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic prophylaxis for onabotulinum toxin A injections: systematic review and meta-analysis.
    Getaneh FW; Simhal R; Sholklapper T; Melvin E; Dorris CS; Chou J; Richter LA; Dieter A
    Int Urogynecol J; 2024 Jan; 35(1):19-29. PubMed ID: 37938397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection.
    Bickhaus JA; Vaughan M; Truong T; Li YJ; Siddiqui NY
    Int Urogynecol J; 2020 Sep; 31(9):1907-1912. PubMed ID: 31989204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
    Patel DN; Jamnagerwalla J; Houman J; Anger JT; Eilber KS
    Int Urogynecol J; 2018 Jul; 29(7):1005-1009. PubMed ID: 28808734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
    Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
    BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Duration of Antibiotic Prophylaxis on Incidence of UTI after OnabotulinumtoxinA Injection.
    Martin S; Zillioux J; Goldman HB; Slopnick E
    Urology; 2022 Aug; 166():140-145. PubMed ID: 35595075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder.
    Lambregts AP; Nieuwhof-Leppink AJ; Klijn AJ; Schroeder RPJ
    J Pediatr Urol; 2022 Jun; 18(3):351.e1-351.e8. PubMed ID: 35283021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity.
    Faure Walker NA; Syed O; Malde S; Taylor C; Sahai A
    Urology; 2019 Jan; 123():242-246. PubMed ID: 30266377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.